Contineum Therapeutics
CTNM | NASDAQ
$9.67
-$0.19 (-1.93%)
At close: Nov 16, 2026, 4:00 PM ET
$9.48
-$0.19 (-1.96%)
After-hours:
Nov 16, 2026, 5:00 PM ET
-1.93%
(1D)No price chart data available for 1D timeframe.
Rating
25.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #915/1021 (Top 90%)
Key Statistics
Market Data
Market Cap $371.23M
1D Range
9.46 9.93
52W Range
7.08 17.57
Valuation (TTM)
PE -5.46
PB 1.51
EV/EBITDA -1.84
Valuation (NTM)
Forward PE N/A
Forward PEG 0.43
Price Target $19.00
Cash Flow
FCF Yield -14.1%
SBC Adj. FCF Yield -18.1%
SBC Impact -28.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
N/A
Dil EPS 3Y | 5Y -18.6% |
N/A
FCF 3Y | 5Y -19.7% |
N/A
Returns
ROA -24.7%
ROE -25.5%
ROIC -28.8%
Financial Health
Net Cash
$238.22M
Current Ratio 31.11
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the...
Sector Healthcare
Industry Biotechnology
Employees 51
IPO Date Apr 4, 2024
Website www.contineum-tx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
4
Consensus
Hold
Price Target
$19.00
Upside
+96.48%
Buy (2)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CTNM